Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

APLM

Apollomics Inc

17.25

Aug 03 • 10:16 AM ET +0.00 (0.03%)

Healthcare Biotechnology USA Nano NASD

Peers: SNTI BRNS CRVO GRDX IGC LSTA NRSN PLRZ SER SKYE

| Held by: CHNA

Scroll to Statements

Index	-
Market Cap	37.88M
Enterprise Value	-
Income	-10.94M
Sales	8.50M
Book/sh	-
Cash/sh	1.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Nov 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	4.46
P/B	-
P/C	11.55
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	0.96
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-7.57
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	50.29% 18.23%
Sales past 3/5Y	- -
EPS Y/Y TTM	86.10%
Sales Y/Y TTM	-
EPS Q/Q	-1224.24%
Sales Q/Q	-
Earnings	Apr 27 BMO
EPS/Sales Surpr.	- -

Insider Own	48.79%
Insider Trans	0.00%
Inst Own	0.03%
Inst Trans	-1.76%
ROA	-110.43%
ROE	-1305.37%
ROIC	-
Gross Margin	-
Oper. Margin	-304.27%
Profit Margin	-128.69%
SMA20	-5.60%
SMA50	0.53%
SMA200	-2.53%
Trades

Shs Outstand	2.20M
Shs Float	1.12M
Short Float	0.90%
Short Ratio	0.56
Short Interest	0.01M
52W High	42.12 -59.05%
52W Low	3.66 371.44%
Volatility	3.52% 10.83%
ATR (14)	1.65
RSI (14)	46.62
Beta	1.45
Rel Volume	0.01
Avg Volume	17.77K
Volume	37

Perf Week	-4.17%
Perf Month	-11.81%
Perf Quarter	6.35%
Perf Half Y	-5.74%
Perf YTD	-7.73%
Perf Year	193.87%
Perf 3Y	-96.91%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	50.00
Prev Close	17.25
Price	17.25
Change	0.03%

Jul-13-26 08:00AM	Apollomics Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) -25.01%
Jun-24-26 04:15PM	Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia (GlobeNewswire) +7.32%
Apr-27-26 08:00AM	Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress (GlobeNewswire)
Apr-01-26 07:00AM	Apollomics Inc. Announces $2.0 Million Bridge Financing (GlobeNewswire) -7.13%
Dec-22-25 04:05PM	Apollomics Reports First Half 2025 Financial Results (GlobeNewswire) +10.55% -6.81%
05:38PM	Loading…
Nov-19-25 05:38PM	Apollomics Announces Settlement of Cayman Litigation (GlobeNewswire) -17.51%
Nov-17-25 11:00PM	Apollomics Announces Changes to its Board of Directors and Composition of Committees (GlobeNewswire) -12.59% -14.50%
Oct-15-25 02:36PM	Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation (GlobeNewswire) +5.79%

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

CEO & Chairman of the BoardMr. Hung-Wen Chen

M.B.A.Mr. K. H. Lin C.A.I.A.

Director & COOMr. Yi-Kuei Chen

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
LIN PETER KUAN-HOW	Chief Financial Officer	Jun 15 '26	Option Exercise	10,000	25,900	Jun 17 07:31 PM
Chen Hung-Wen	Chief Executive Officer	Jun 15 '26	Option Exercise	5,000	148,334	Jun 16 05:11 PM
CHU YI-AN	Director	Jun 15 '26	Option Exercise	500	1,500	Jun 16 05:09 PM
CHEN HONG-JUNG	Director	Jun 15 '26	Option Exercise	500	3,620	Jun 16 05:08 PM
TSAI HSIEN-SHU	Director	Jun 15 '26	Option Exercise	500	1,500	Jun 16 05:05 PM
Chen Yi-Kuei	Chief Operating Officer	Jun 15 '26	Option Exercise	5,000	15,000	Jun 16 05:01 PM
Jan Chen-Huan	Director	Jun 15 '26	Option Exercise	500	1,500	Jun 16 05:01 PM
Huang Ya-Chi	Director	May 17 '26	Option Exercise	500	1,000	May 19 12:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLM

Apollomics Inc

Upgrade your Finviz experience